Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.